Population homogeneity for the antibody response to COVID-19 BNT162b2 / Comirnaty vaccine is only reached after the second dose, across all adult age ranges

Viana, João Faro; Bergman, Marie‐Louise; Gonçalves, Lígia Antunes; Duarte, Nádia; Coutinho, Teresa P.; Borges, Patrícia; Diwo, Christian; Matoso, Paula; Malheiro, Vanessa; Brennand, Ana; Kosack, Lindsay; Akpogheneta, Onome; Figueira, José Rui; Cardoso, Conceição; Casaca, Ana M; Alves, Paula M.; Nunes, Teresa; Penha‐Gonçalves, Carlos; Demengeot, Jocelyne

doi:10.1101/2021.03.19.21253680

Cited by 10 publications

(15 citation statements)

References 32 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this association nearly vanished after dose 2 and lost statistical significance (ρ=-0.23, P=0.093). These findings align with recent articles, which found a gap in antibody levels of younger and older individuals after dose 1 ( Abu Jabal et al, 2021 , Müller et al, 2021 , Viana et al, 2021 ). A recently published prospective study by Lustig et al (2021) confirmed that older adults yield lower antibody levels after the first BNT162b2 dose, with the age groups converging after the second dose.…”

Section: Discussionsupporting

confidence: 92%

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222

Perkmann¹,

Perkmann-Nagele²,

Mucher³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objectives : Our objective was to determine whether SARS-CoV-2 antibody levels after the first dose can predict the final antibody response and whether this is dependent on the vaccine type. Methods : 69 BNT162b2 (Pfizer/BioNTech) and 55 AZD1222 (AstraZeneca) vaccinees without previous infection or immunosuppressive medication were included. Anti-body levels were quantified 3 weeks after dose 1, in case of AZD1222 directly before boostering (11 weeks after dose 1) and 3 weeks after dose 2, with the Roche SARS-CoV-2 S total antibody assay. Results : Pre-booster (BNT162b2: 80.6 [25.5-167.0] BAU/mL, AZD1222: 56.4 [36.4-104.8] BAU/mL, not significant) and post-booster levels (BNT162b2: 2,092.0 [1,216.3-4,431.8] BAU/mL, AZD1222: 957.0 [684.5-1,684.8] BAU/mL, p<0.0001) correlated well in BNT162b2 (ρ=0.53) but not in AZD1222 recipients. Moreover, antibody levels after the first dose of BNT162b2 correlated inversely with age (ρ=-0.33, P=0.013), whereas a positive correlation with age was observed after the second dose in AZD1222 recipients (ρ=0.26, P=0.030). Conclusions : In conclusion, our data suggest that antibody levels quantified by the Roche Elecsys SARS-CoV-2 S assay before the booster shot could infer post-booster responses to BNT162b2, but not to AZ1222. In addition, we found a vaccine-dependent effect on antibody responses, where age seems to play an ambivalent role.

show abstract

Section: Discussionsupporting

confidence: 92%

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222

Perkmann¹,

Perkmann-Nagele²,

Mucher³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…However, IgG levels after one vaccine dose were remarkably lower in hemodialysis patients when compared to age-matched controls below 70y. These results strengthen that the dynamics of anti-IgG responses across the vaccination schedule in hemodialyzed patients resembles those of elderly cohorts (8).…”

Section: Discussionsupporting

confidence: 78%

“…Our observations added to mounting evidence that age has a significant negative effect on antibody response to the BNT162b2 vaccine (5,6,8). However, IgG levels after one vaccine dose were remarkably lower in hemodialysis patients when compared to age-matched controls below 70y.…”

Section: Discussionsupporting

confidence: 58%

“…The study enrolled 156 patients with stage 5 chronic kidney disease (CKD) undergoing renal replacement therapy as outpatients at a hemodialysis clinic (Davita, Eurodial) in Óbidos, Portugal. An age-matched control cohort without kidney disease comprised 143 individuals randomly selected from a larger cohort of 1245 Health care workers and 146 nursing home residents (8). All Participants initiated BNT162b2 mRNA vaccination (Comirnaty®, Pfizer/BioNTech) according the established schedule of 2 doses with a 3 weeks interval.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Longitudinal analysis of antibody responses to the Pfizer BNT162b2 vaccine in Patients Undergoing Maintenance Hemodialysis

Weigert

Bergman

Gonçalves

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background and objectives: Patients undergoing hemodialysis are at higher risk of developing severe complications upon SARS-CoV-2 infection and were prioritized in the Portuguese vaccination campaign. Immunogenicity of COVID-19 vaccines in hemodialyzed patients was not addressed by the phase 3 clinical trials leading to their emergency approval. Design, setting, participants, and measurements: We performed a prospective, longitudinal, cohort analysis of 156 hemodialyzed patients and 143 age-matched controls scheduled for BTN162b2 vaccine. Excluded from analysis were five patients previously diagnosed with SARS-CoV-2, three sero-positive for anti-SARS-CoV-2 N, two dropouts and two deaths. ELISA was used to quantify anti-full-length Spike IgG, IgM and IgA levels in sera collected at day of the first vaccine dose (t0); 3 weeks later (day of the second dose, t1); and 3 weeks after the second inoculation (t2). Results: Seroconversion after the first vaccine dose (t1) was remarkably low in patients, with positivity for anti-spike IgG, IgM and IgA antibodies of 29.4%, 12% and 41%, respectively. The second vaccine dose raised seroconversion to 90.9% and 83.9% for IgG and IgA, respectively, while IgM positivity remained unchanged. At t1 the anti-Spike IgG level was significantly lower in patients with ages below 70 years when compared to age-matched controls, showing a profile similar to aged individuals (above 70 years). Immunosuppression was associated with lower antibody responses along the vaccine schedule (p=0.005 at t1; p=0.008 at t2). Noteworthy, previous unresponsiveness to hepatitis B vaccination (75/129, 58% of patients negative for anti-HBs antibodies) did not correlate with humoral unresponsiveness to BTN162b2. Other clinical and laboratory parameters had marginal correlations with response to vaccination. Conclusions: The large majority of hemodialyzed patients showed IgG seroconversion upon BNT162b2 mRNA vaccination but a sizable proportion of patients presented poor responses. These results support further investigation into the relationship between vaccination, serologic response and host protection.

show abstract

Section: Discussionsupporting

confidence: 92%

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222

Perkmann¹,

Perkmann-Nagele²,

Mucher³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives Our objective was to determine whether SARS-CoV-2 antibody levels after the first dose can predict the final antibody response and whether this is dependent on the vaccine type. Methods 69 BNT162b2 (Pfizer/BioNTech) and 55 AZD1222 (AstraZeneca) vaccinees without previous infection or immunosuppressive medication were included. Anti-body levels were quantified 3 weeks after dose 1, in case of AZD1222 directly before boostering (11 weeks after dose 1) and 3 weeks after dose 2, with the Roche SARS-CoV-2 S total antibody assay. Results Pre-booster (BNT162b2: 80.6 [25.5-167.0] BAU/mL, AZD1222: 56.4 [36.4-104.8] BAU/mL, not significant) and post-booster levels (BNT162b2: 2,092.0 [1,216.3-4,431.8] BAU/mL, AZD1222: 957.0 [684.5-1,684.8] BAU/mL, p<0.0001) correlated well in BNT162b2 (ρ=0.53) but not in AZD1222 recipients. Moreover, antibody levels after the first dose of BNT162b2 correlated inversely with age (ρ=-0.33, P=0.013), whereas a positive correlation with age was observed after the second dose in AZD1222 recipients (ρ=0.26, P=0.030). Conclusions In conclusion, our data suggest that antibody levels quantified by the Roche Elecsys SARS-CoV-2 S assay before the booster shot could infer post-booster responses to BNT162b2, but not to AZ1222. In addition, we found a vaccine-dependent effect on antibody responses, suggesting a possible link between vaccine response and vector immunity.

show abstract

Population homogeneity for the antibody response to COVID-19 BNT162b2 / Comirnaty vaccine is only reached after the second dose, across all adult age ranges

Cited by 10 publications

References 32 publications

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222

Longitudinal analysis of antibody responses to the Pfizer BNT162b2 vaccine in Patients Undergoing Maintenance Hemodialysis

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222

Contact Info

Product

Resources

About